https://dallasinnovates.com/14-emerging-tech-trends-for-2021-and-dallas-area-companies-that-are-innovating-for-the-future/#new_tab2021-03-19T01:45:24-05:00https://dallasinnovates.com/two-techfw-clients-receive-awards-from-nasa-and-the-national-eye-institute/#new_tab2021-03-19T01:45:52-05:00https://www.dallasnews.com/business/health-care/2018/09/24/bedford-biomedical-firm-wins-major-backing-for-tech-that-could-restore-damaged-retinas/#new_tab2021-03-19T01:42:37-05:00https://dallasinnovates.com/nanoscope-therapeutics-closes-series-a-names-alvaro-guillem-as-chairman/2021-03-19T01:44:43-05:00https://www.thetimes.co.uk/article/human-trials-for-genetic-jab-that-lets-blind-mice-see-again-q0p7sx8hd#new_tab2021-03-24T10:03:11-05:00https://www.dailymail.co.uk/sciencetech/article-8867017/Scientists-use-light-sensing-protein-restore-vision.html#new_tab2021-03-24T10:04:42-05:00https://www.nature.com/articles/s41587-021-00823-9#new_tab2021-04-07T17:29:16-05:00https://www.nature.com/articles/s41434-020-00200-2#new_tab2021-05-19T13:00:10-05:00https://www.ophthalmologytimes.com/view/optogenetic-gene-therapy-restores-vision-in-11-rp-patients#new_tab2021-06-24T14:02:38-05:00https://www.citybiz.co/article/75164/nanoscopes-optogenetic-gene-therapy-restores-clinically-meaningful-vision-in-11-patients-blinded-by-retinitis-pigmentosa/#new_tab2021-06-03T19:01:50-05:00https://www.dallasnews.com/business/health-care/2021/06/04/bedford-biotechs-gene-therapy-improves-sight-for-11-patients-with-a-rare-genetic-retina-disorder/#new_tab2021-06-08T11:36:19-05:00https://fortworthbusiness.com/business/north-texas-biotechnology-company-shows-vision-improvement-via-gene-therapy#new_tab2021-06-08T11:36:08-05:00https://www.forbes.com/sites/carolineseydel/2021/06/13/what-is-optogenetics-behind-the-technology-thats-bringing-sight-to-the-blind/?sh=1986e780493bhttps://fortworthbusiness.com/business/north-texas-biotechnology-company-shows-vision-improvement-via-gene-therapy#new_tab2021-06-16T11:30:58-05:00https://dallasinnovates.com/bedford-biotech-restores-meaningful-vision-in-blind-patients-with-gene-therapy-and-may-soon-go-public/#new_tab2021-06-22T21:16:41-05:00https://www.dallasnews.com/business/health-care/2021/06/23/bedford-biotechs-eyesight-restoring-gene-therapy-receives-fda-approval-to-test-in-the-us/?outputType=amp#new_tab2021-07-23T15:10:54-05:00https://fortworthbusiness.com/business/nanoscope-therapeutics-cleared-to-open-phase-2b-clinical-trial-for-vision-therapy/#new_tab2021-06-23T11:47:41-05:00https://www.biospace.com/article/releases/nanoscope-therapeutics-announces-fda-approval-of-ind-for-phase-2b-clinical-trial-of-optogenetic-gene-monotherapy-to-restore-vision-in-patients-with-retinitis-pigmentosa/#new_tab2021-06-24T11:15:16-05:00https://www.biospace.com/article/releases/nanoscope-therapeutics-announces-fda-approval-of-ind-for-phase-2b-clinical-trial-of-optogenetic-gene-monotherapy-to-restore-vision-in-patients-with-retinitis-pigmentosa/#new_tab2021-06-24T14:02:51-05:00https://fortworthinc.com/news/bedford-s-nanoscope-begins-human-trial-of-drug-for-retinitis/#new_tab2021-07-23T15:08:02-05:00https://www.fightingblindness.org/research/nanoscope-therapeutics-launches-phase-2b-clinical-trial-for-optogenetic-therapy-229#new_tab2021-07-23T15:13:21-05:00https://www.ophthalmologytimes.com/view/first-patient-dosed-in-optogenetic-gene-therapy-trial#new_tab2021-07-23T15:10:03-05:00https://www.modernretina.com/view/optogenetic-gene-therapy-trial-begins-first-patient-dosed#new_tab2021-08-04T15:16:31-05:00https://www.bio.org/blogs/pandemic-highlights-need-more-women-scientists#new_tab2021-08-04T15:16:27-05:00https://retinatoday.com/articles/2021-july-aug/aav-gene-therapy-trials-to-watch?c4src=home:feed#new_tab2021-08-04T15:16:38-05:00https://fortworthbusiness.com/business/first-patient-receives-innovative-gene-therapy-eye-treatment-from-techfw-client/#new_tab2021-08-04T15:18:13-05:00https://www.scienceboard.net/index.aspx?sec=ser&sub=def&pag=dis&ItemID=3035#new_tab2021-08-23T12:15:37-05:00https://dallasinnovates.com/nanoscope-awarded-1-5m-grant-for-eyesight-gene-therapy-as-it-takes-steps-to-go-public/#new_tab2021-09-17T10:42:07-05:00https://fortworthbusiness.com/health-care/techfw-client-nanoscope-receives-1-5m-grant-to-move-macular-degeneration-therapy-forward/#new_tab2021-09-21T12:34:02-05:00https://www.frontiersin.org/articles/10.3389/fncel.2021.750663/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Cellular_Neuroscience&id=750663#new_tab2025-05-23T11:54:59-05:00https://www.frontiersin.org/articles/10.3389/fnins.2021.750684/full#new_tab2025-05-23T11:54:52-05:00https://nanostherapeutics.com/wp-content/uploads/2022/01/NSCOPE_showdaily2201-4SINGLEPAGE-copy.pdf#new_tab2022-01-22T12:05:17-06:00https://www.ophthalmologytimes.com/view/nanoscope-therapeutics-announces-fda-clearance-of-ind-for-mco-010-gene-therapy-in-stargardt-patients#new_tab2022-01-25T13:38:45-06:00https://www.healio.com/news/ophthalmology/20220125/gene-therapy-platform-for-stargardt-macular-degeneration-receives-ind-clearance#new_tab2022-01-25T13:39:44-06:00https://nanostherapeutics.com/2022/02/07/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision/2025-07-25T11:13:50-05:00https://www.youtube.com/watch?v=IdxDarzr9QY#new_tab2022-07-04T12:16:22-05:00https://www.ophthalmologytimes.com/view/nanoscope-therapeutics-announces-first-patient-dosed-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease#new_tab2022-07-26T14:14:12-05:00https://www.healio.com/news/ophthalmology/20220726/phase-2-gene-therapy-trial-for-stargardt-disease-underway#new_tab2023-09-26T15:17:16-05:00https://www.cgtlive.com/view/nanoscope-gene-therapy-continues-progress-in-stargardt-disease#new_tab2022-07-26T14:16:22-05:00https://www.citybiz.co/article/298022/techfw-member-nanoscope-starts-second-stage-2-trial/#new_tab2022-08-16T11:43:04-05:00https://dallasinnovates.com/meet-the-43-finalists-for-the-2022-tech-titans-awards/#new_tab2022-09-09T13:36:07-05:00https://nanostherapeutics.com/2022/09/13/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease/2025-07-25T11:23:37-05:00https://euretinacongressdaily.org/making-headway-in-the-battle-against-inherited-retinal-diseases/#new_tab2022-09-15T19:09:00-05:00https://www.ophthalmologytimes.com/view/enrollment-completed-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease#new_tab2022-09-15T19:09:14-05:00https://www.healio.com/news/ophthalmology/20221011/retinitis-pigmentosa-treatment-receives-fast-track-designation#new_tab2022-11-10T11:01:06-06:00https://www.modernretina.com/view/fda-grants-fast-track-designation-to-nanoscope-therapeutics-for-mco-010-for-the-treatment-of-retinitis-pigmentosa#new_tab2022-11-10T11:01:00-06:00https://www.cgtlive.com/view/10-cell-and-gene-therapies-to-watch-in-2023#new_tab2023-01-25T12:12:24-06:00https://www.modernretina.com/view/nanoscope-therapeutics-announces-who-selection-of-sonpiretigene-isteparvovec-as-international-nonproprietary-name-for-mco-010#new_tab2023-03-01T19:02:57-06:00https://dallasinnovates.com/the-future-50-in-dallas-fort-worth-2023-meet-the-game-changing-disruptors-driving-innovation-and-impact/#new_tab2023-03-17T12:31:39-05:00https://www.fiercebiotech.com/biotech/nanoscopes-phase-2-win-gene-therapy-shows-potential-light-sensitive-approach-eye-disease#new_tab2023-03-30T11:27:05-05:00https://www.clinicaltrialsarena.com/news/nanoscopes-gene-therapy-nabs-phase-ii-win-in-retinitis-pigmentosa/#new_tab2023-03-30T11:32:02-05:00https://globalgenes.org/raredaily/nanoscope-reports-positive-topline-results-from-phase-2b-trial-of-mco-010-for-the-treatment-of-retinitis-pigmentosa/#new_tab2023-04-10T11:32:37-05:00https://www.ophthalmologytimes.com/view/nanoscope-therapeutics-presents-results-from-phase-2b-restore-trial-of-mco-010-for-treatment-of-retinitis-pigmentosa#new_tab2023-04-28T11:56:08-05:00https://www.clinicaltrialsarena.com/news/nanoscope-therapeutics-retinitis-pigmentosa-mco-010/#new_tab2023-04-28T11:56:02-05:00https://www.fightingblindness.org/news/eyecurepodcast-305#new_tab2023-05-24T11:32:00-05:00https://www.healio.com/news/ophthalmology/20230804/video-early-data-on-optogenetic-therapy-in-stargardt-disease-promising#new_tab2023-08-12T16:45:38-05:00https://www.ophthalmologytimes.com/view/asrs-2023-the-starlight-study#new_tab2023-08-12T17:18:58-05:00https://retinatoday.com/articles/2023-july-aug/the-latest-in-gene-therapy-clinical-trials-for-ird?c4src=issue:feed#new_tab2023-09-26T15:24:38-05:00https://www.modernretina.com/view/gene-therapy-what-s-to-come-#new_tab2023-10-05T12:02:51-05:00https://www.healio.com/news/ophthalmology/20231013/video-optogenetic-therapy-shows-promise-in-advanced-retinitis-pigmentosa#new_tab2023-10-17T11:20:43-05:00https://nanostherapeutics.com/2023/11/03/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023/2025-06-27T11:28:56-05:00https://nanostherapeutics.com/2023/11/09/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit/2025-06-27T11:28:27-05:00https://eyewire.news/news/nanoscope-therapeutics-wins-best-of-show-award-at-aao-eyecelerator-2023?c4src=article:infinite-scroll#new_tab2023-11-10T06:35:10-06:00https://www.modernretina.com/view/mco-010-optogenetic-gene-therapy-for-severe-vision-loss-in-stargardt-disease#new_tab2024-08-11T18:47:32-05:00https://nanostherapeutics.com/2023/11/30/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii/2025-06-27T11:27:51-05:00https://thehealthcaretechnologyreport.com/the-top-25-women-leaders-in-biotechnology-of-2023/#new_tab2023-11-30T08:37:08-06:00https://nanostherapeutics.com/2023/12/01/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress/2025-06-27T11:27:31-05:00https://nanostherapeutics.com/2023/12/04/glenn-sblendorio-as-chairman-of-the-board/2025-06-27T11:27:04-05:00https://nanostherapeutics.com/2024/01/12/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference/2025-06-27T11:25:23-05:00https://nanostherapeutics.com/2024/01/18/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa/2025-06-27T11:24:42-05:00https://nanostherapeutics.com/2024/02/01/nanoscope-therapeutics-announces-presentation-at-bascom-palmer-eye-institutes-21st-annual-angiogenesis-exudation-and-degeneration-meeting/2025-06-27T11:22:30-05:00https://nanostherapeutics.com/2024/02/07/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting/2025-06-27T11:22:09-05:00https://nanostherapeutics.com/2024/02/12/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting/2025-06-27T11:21:50-05:00https://nanostherapeutics.com/2024/02/14/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit/2025-06-27T11:21:28-05:00https://nanostherapeutics.com/2024/02/21/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2/2025-06-27T11:21:06-05:00https://nanostherapeutics.com/2024/03/26/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa/2025-06-27T11:20:37-05:00https://www.fiercebiotech.com/biotech/nanoscope-eyes-market-after-gene-therapy-improves-vision-patients-retinal-disease#new_tab2024-03-26T07:35:36-05:00https://pharmaphorum.com/news/nanoscope-preps-filing-retinitis-pigmentosa-gene-therapy#new_tab2024-03-26T07:39:42-05:00https://nanostherapeutics.com/2024/04/17/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024/2025-06-27T11:19:59-05:00https://nanostherapeutics.com/2024/04/25/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor/2025-06-27T11:19:33-05:00https://nanostherapeutics.com/2024/04/29/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits/2025-06-27T11:19:04-05:00https://nanostherapeutics.com/2024/05/02/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2/2025-06-27T11:18:38-05:00https://nanostherapeutics.com/2024/05/07/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress/2025-06-27T11:18:14-05:00https://nanostherapeutics.com/2024/05/14/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality/2025-06-27T11:17:42-05:00https://nanostherapeutics.com/2024/05/07/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2/2025-06-27T11:43:50-05:00https://nanostherapeutics.com/2024/05/29/nanoscope-therapeutics-to-present-at-the-bio-international-convention/2025-06-27T11:17:03-05:00https://nanostherapeutics.com/2024/06/19/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect/2025-06-27T11:16:41-05:00https://nanostherapeutics.com/2024/07/10/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting/2025-06-27T11:15:40-05:00https://nanostherapeutics.com/2024/08/08/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference/2025-06-27T11:15:09-05:00https://www.modernretina.com/view/asrs-2024-restore-trial-100-week-results#new_tab2024-08-11T18:35:20-05:00https://www.modernretina.com/view/nanoscope-therapeutics-lead-candidate-mco-010-meets-endpoints-in-restore-trial-for-retinitis-pigmentosa#new_tab2024-08-11T18:46:21-05:00https://www.healio.com/news/ophthalmology/20240808/video-mco010-for-retinitis-pigmentosa-improves-vision-in-phase-2b3-study#new_tab2024-11-08T17:34:12-06:00https://www.pharmaceutical-technology.com/analyst-comment/nanoscope-therapeutics-positive-top-line-phase-iib-results-mco-010/?cf-view#new_tab2024-08-11T18:46:15-05:00https://www.healio.com/news/ophthalmology/20240327/gene-therapy-improves-vision-in-patients-with-retinitis-pigmentosa-in-phase-2b-trial#new_tab2024-08-11T18:43:20-05:00https://www.healio.com/news/ophthalmology/20240507/video-optogenetic-therapy-shows-vision-improvements-safety-at-12-months#new_tab2024-08-11T18:46:07-05:00https://longevity.technology/news/nanoscope-targets-fda-approval-following-positive-gene-therapy-trial-results/#new_tab2024-08-11T18:49:49-05:00https://www.modernretina.com/view/euretina-2023-safety-and-efficacy-through-week-48-in-the-phase-2a-starlight-clinical-trial#new_tab2024-08-11T18:53:10-05:00https://dallasinnovates.com/people-nanoscope-therapeutics-appoints-industry-veteran-as-strategic-adviser/#new_tab2024-08-11T18:55:52-05:00https://nanostherapeutics.com/2024/09/09/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon/2025-06-27T08:38:43-05:00https://nanostherapeutics.com/2024/09/12/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration/2025-06-27T11:13:06-05:00https://nanostherapeutics.com/2024/09/16/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona/2025-06-27T11:11:21-05:00https://nanostherapeutics.com/2024/09/19/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona/2024-09-19T16:52:49-05:00https://nanostherapeutics.com/2024/09/19/nanoscope-therapeutics-to-be-featured-at-annual-euretina-congress-in-barcelona-2/2025-06-27T10:57:08-05:00https://nanostherapeutics.com/2024/09/30/nanoscope-therapeutics-licenses-optogenetic-catch-technology/2025-06-27T10:42:26-05:00https://www.mpg.de/23529628/0930-mpin-nanoscope-therapeutics-licenses-optogenetic-technology-1160219-x?c=2249#new_tab2024-10-06T11:57:14-05:00https://www.retina-specialist.com/article/highlights-of-arvo-2024#new_tab2024-11-08T17:34:18-06:00https://www.hcplive.com/view/nanoscope-reports-positive-end-of-phase-2-meeting-for-mco-010-gene-therapy#new_tab2024-11-08T17:34:05-06:00https://nanostherapeutics.com/2024/10/10/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa/2025-06-27T08:35:21-05:00https://nanostherapeutics.com/2024/10/15/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024/2025-06-27T08:34:47-05:00https://nanostherapeutics.com/2024/10/21/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration/2025-06-27T08:34:07-05:00https://nanostherapeutics.com/2024/10/31/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa/2025-06-27T11:07:05-05:00https://nanostherapeutics.com/2024/11/07/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors/2025-06-27T11:04:05-05:00https://ophthalmology360.com/inherited-retinal-disease/two-year-results-of-restore-study-highlight-a-mutation-agnostic-gene-therapy-for-retinitis-pigmentosa/#new_tab2024-11-08T17:17:42-06:00https://www.healio.com/news/ophthalmology/20241028/video-nanoscope-therapeutics-shares-status-update#new_tab2024-11-08T17:19:19-06:00https://www.healio.com/news/ophthalmology/20241021/video-optogenetic-therapy-trial-in-retinitis-pigmentosa-meets-safety-efficacy-endpoints#new_tab2024-11-08T17:21:15-06:00https://www.hcplive.com/view/allen-c-ho-md-efficacy-safety-of-mco-010-for-retinitis-pigmentosa-at-2-years#new_tab2024-11-08T17:23:18-06:00https://www.ophthalmologytimes.com/view/aao-2024-new-gene-therapy-shows-promise-for-treatment-of-retinitis-pigmentosa#new_tab2024-11-08T17:33:55-06:00https://www.healio.com/news/ophthalmology/20241001/video-optogenetic-therapy-shows-promise-for-inherited-retinal-dystrophies#new_tab2024-11-08T17:28:11-06:00https://nanostherapeutics.com/2024/11/11/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia/2025-06-27T08:32:13-05:00https://nanostherapeutics.com/2024/12/02/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress/2025-06-27T08:31:42-05:00https://nanostherapeutics.com/2024/12/05/ray-kaczmarek-joins-nanoscope/2025-06-27T08:31:14-05:00https://nanostherapeutics.com/2025/01/09/nanoscope-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference/2025-06-27T08:25:13-05:00https://nanostherapeutics.com/2025/01/20/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference/2025-07-13T15:11:42-05:00https://nanostherapeutics.com/2025/02/04/nanoscope-announces-presentations-at-medical-meetings/2025-07-13T15:11:27-05:00https://nanostherapeutics.com/2025/02/06/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference/2025-07-13T15:11:11-05:00https://veranahealth.com/verana-health-and-nanoscope-therapeutics-announce-collaboration-to-accelerate-retinitis-pigmentosa-research/?utm_campaign=LS%20%7C%20Qdata%20Retinitis%20Pigmentosa&utm_content=325847607&utm_medium=social&utm_source=linkedin&hss_channel=lcp-3859106#new_tab2025-07-13T15:10:57-05:00https://nanostherapeutics.com/2025/03/05/hc-wainwright-bioconnect-2025/2025-07-13T15:10:40-05:00https://nanostherapeutics.com/2025/03/05/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access/2025-09-22T16:39:43-05:00https://nanostherapeutics.com/2025/03/20/nanoscope-therapeutics-announces-the-appointment-of-ademola-daramola-d-sc-as-vice-president-quality-compliance/2025-07-13T15:10:24-05:00https://nanostherapeutics.com/2025/03/24/nanoscope-announces-publication-of-clinical-data-on-vision-restoration-in-retinitis-pigmentosa/2025-07-13T15:10:10-05:00https://nanostherapeutics.com/2025/03/27/ashish-patel-phd-joins-nanoscope-as-senior-vice-president-of-sales-and-marketing/2025-07-13T15:09:52-05:00https://ophthalmologybreakingnews.com/nanoscope-therapeutics-publishes-clinical-data#new_tab2025-07-23T13:50:13-05:00https://www.cell.com/molecular-therapy/fulltext/S1525-0016(25)00205-9#new_tab2025-06-05T11:01:07-05:00https://nanostherapeutics.com/2025/04/26/nanoscope-participation-at-eyecelerator-and-arvo-2025/2025-07-13T15:09:30-05:00https://nanostherapeutics.com/2025/05/01/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration/2025-07-13T15:09:16-05:00https://nanostherapeutics.com/2025/05/12/nanoscope-to-present-research-at-asgct2025/2025-05-23T11:18:35-05:00https://nanostherapeutics.com/2025/07/02/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting/2025-07-13T15:09:02-05:00https://pubmed.ncbi.nlm.nih.gov/34418301/#new_tab2025-06-05T11:02:15-05:00https://pubmed.ncbi.nlm.nih.gov/28840163/#new_tab2025-06-05T11:02:46-05:00https://pubmed.ncbi.nlm.nih.gov/39412768/#new_tab2025-06-05T11:01:55-05:00https://pubmed.ncbi.nlm.nih.gov/39441604/#new_tab2025-06-05T11:01:28-05:00https://pubmed.ncbi.nlm.nih.gov/33087861/#new_tab2025-06-05T11:02:34-05:00https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(25)00292-8#new_tab2025-07-23T18:40:00-05:00https://www.modernretina.com/view/victor-gonzalez-md-shares-research-findings-on-vision-restoration-in-patients-with-retinitis-pigmentosa-clinical-trials-summit#new_tab2025-06-22T14:29:26-05:00https://www.modernretina.com/view/optogenetics-for-retinal-disease#new_tab2025-06-22T14:32:55-05:00https://www.healio.com/news/ophthalmology/20250613/gene-therapy-shows-longterm-visual-acuity-improvements-in-retinitis-pigmentosa#new_tab2025-06-22T14:36:50-05:00https://nanostherapeutics.com/2025/06/26/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee/2025-07-13T15:08:42-05:00https://www.medscape.org/viewarticle/1002678#new_tab2025-07-23T13:50:03-05:00https://nanostherapeutics.com/2025/07/14/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa/2025-07-23T18:39:41-05:00https://nanostherapeutics.com/2025/07/22/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology/2025-07-23T18:30:25-05:00https://advanced.onlinelibrary.wiley.com/doi/10.1002/adtp.202500009#new_tab2025-07-23T18:39:48-05:00https://piemagazine.org/nanoscope-bla-submission-rp-therapy-advisory-board/#new_tab2025-07-23T13:52:33-05:00https://www.healio.com/news/ophthalmology/20250714/nanoscope-begins-rolling-submission-of-biologics-license-application-for-rp-gene-therapy#new_tab2025-07-23T13:53:49-05:00https://www.modernretina.com/view/fda-grants-nanoscope-rolling-bla-submission-of-mco-010#new_tab2025-07-23T13:55:30-05:00https://eyewire.news/news/nanoscope-initiates-rolling-submission-of-bla-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-rp?c4src=article:infinite-scroll#new_tab2025-07-23T13:57:30-05:00https://nanostherapeutics.com/2025/07/28/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting/2025-07-28T07:26:51-05:00https://nanostherapeutics.com/2025/08/14/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease/2025-08-14T09:45:07-05:00https://www.sciencedirect.com/science/article/pii/S2589537025003621#new_tab2025-08-19T15:27:45-05:00https://nanostherapeutics.com/2025/08/26/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting/2025-09-02T06:25:04-05:00https://nanostherapeutics.com/2025/09/02/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations/2025-10-13T06:34:02-05:00https://nanostherapeutics.com/2025/10/13/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting/2025-10-13T07:34:38-05:00https://nanostherapeutics.com/2025/10/22/nanoscope-therapeutics-announces-durable-3-year-vision-improvements-from-remain-study-of-mco-010-in-retinitis-pigmentosa/2025-10-22T18:30:15-05:00https://www.ophthalmologytimes.com/view/aao-2025-kenneth-c-fan-md-sees-vision-gains-with-mco-010-in-stargardt-disease#new_tab2025-10-22T18:29:04-05:00https://www.retinalphysician.com/issues/2025/october/aao23/#new_tab2025-10-22T18:37:53-05:00https://piemagazine.org/sheets-chips-and-switches-practical-paths-to-vision-restoration/#new_tab2025-10-22T18:36:31-05:00https://nanostherapeutics.com/2025/10/27/nanoscope-therapeutics-president-and-chief-scientific-officer-dr-samarendra-mohanty-to-be-featured-speaker-at-2025-ispe-annual-meeting-and-expo/2025-10-27T06:32:19-05:00https://nanostherapeutics.com/2025/11/04/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa/2025-11-04T10:07:10-06:00https://nanostherapeutics.com/2025/11/17/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025/2025-12-02T06:51:51-06:00https://nanostherapeutics.com/2025/12/02/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress/2026-01-05T06:40:46-06:00https://nanostherapeutics.com/2026/01/05/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference/2026-02-24T06:41:48-06:00https://nanostherapeutics.com/2026/01/05/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration/2026-02-24T06:41:37-06:00https://nanostherapeutics.com/2026/01/20/nanoscope-secures-japan-mhlw-sakigake-and-orphan-drug-designations-across-inherited-retinal-diseases-a-first-for-a-retinal-gene-therapy/2026-02-24T06:42:00-06:00https://nanostherapeutics.com/2026/02/24/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting/2026-02-24T06:49:19-06:00https://nanostherapeutics.com/2026/03/23/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease/2026-03-23T08:24:28-05:00https://nanostherapeutics.com/2026/03/30/nanoscope-therapeutics-receives-orphan-drug-designation-in-saudi-arabia-for-mco-010-expands-global-regulatory-leadership-in-vision-restoration/2026-03-30T07:31:03-05:00https://nanostherapeutics.com/2026/04/01/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness/2026-04-01T06:17:26-05:00